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Abstract
Osteoblasts form an epithelium-like layer with tight junctions separating bone
matrix from extracellular fluid. During mineral deposition, calcium and phos-
phate precipitation in hydroxyapatite liberates 0.8 mole of H+ per mole Ca+2.
Thus, acid export is needed for mineral formation. We examined ion trans-
port supporting osteoblast vectorial mineral deposition. Previously we estab-
lished that Na/H exchangers 1 and 6 are highly expressed at secretory
osteoblast basolateral surfaces and neutralize massive acid loads. The Na/H
exchanger regulatory factor-1 (NHERF1), a pdz-organizing protein, occurs at
mineralizing osteoblast basolateral surfaces. We hypothesized that high-capa-
city proton transport from matrix into osteoblast cytosol must exist to sup-
port acid transcytosis for mineral deposition. Gene screening in mineralizing
osteoblasts showed dramatic expression of chloride–proton antiporters ClC-3
and ClC-5. Antibody localization showed that ClC-3 and ClC-5 occur at the
apical secretory surface facing the bone matrix and in membranes of buried
osteocytes. Surprisingly, the Clcn3/ mouse has only mildly disordered min-
eralization. However, Clcn3/ osteoblasts have large compensatory increases
in ClC-5 expression. Clcn3/ osteoblasts mineralize in vitro in a striking and
novel trabecular pattern; wild-type osteoblasts form bone nodules. In mes-
enchymal stem cells from Clcn3/ mice, lentiviral ClC-5 shRNA created
Clcn3/, ClC-5 knockdown cells, validated by western blot and PCR. Osteo-
blasts from these cells produced no mineral under conditions where wild-type
or Clcn3/ cells mineralize well. We conclude that regulated acid export,
mediated by chloride–proton exchange, is essential to drive normal bone
mineralization, and that CLC transporters also regulate fine patterning of
bone.
Introduction
In mammals, bone formation occurs behind a tight
epithelium-like layer of osteoblasts that produce bone
matrix components and regulate the environment for
bone matrix assembly. The components are mainly type I
collagen, calcium, and phosphate. These are produced by
osteoblasts via well-studied mechanisms (Blair et al. 2007,
2011). However, sealed inside the physiologic bone bio-
generator, the osteon, additional transport across the
epithelium-like osteoblasts is critical for mineral deposi-
tion. Specifically, precipitation of hydroxyapatite from
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calcium and phosphate solutions in a sealed compartment
liberates a massive amount of acid, equation (1).
6HPO24 þ 2H2Oþ 10Ca2þ  Ca10ðPO4Þ6ðOHÞ2 þ 8Hþ
(1)
Equation (1) implies that, during mineral synthesis, by
removing acid mineral precipitation in the matrix com-
partment can be driven effectively to completion regard-
less of extracellular conditions, since matrix is isolated
from extracellular fluid. This holds as long as transport of
soluble components into the matrix space, and of acid
out, is maintained. Furthermore, the chemistry shown in
equation (1) demands that bone cannot mineralize if the
protons are not removed; mineral formation stops at pH
below 5.6 (Neuman and Neuman 1958). Until recently,
the mechanism of proton transport was entirely
unknown, primarily because it was not studied systemati-
cally. Similarly, the mechanism of the reverse process,
acidification to solubilize bone mineral by the osteoclast,
was unclear until studied (Blair et al. 1989, 1991; Teti
et al. 1989; Schlesinger et al. 1994).
Our recent studies of the mineralizing unit, or osteon,
showed that sodium–hydrogen exchangers 1 and 6
(NHE1 and NHE6) are highly expressed at the basolateral
surface of mineralizing osteoblasts (Liu et al. 2011), along
with the PDZ-organizing protein sodium–hydrogen
exchanger regulatory factor 1 (NHERF1). This makes the
surface of the osteon a powerful organelle for secreting
acid into the extracellular fluid (Liu et al. 2012). Comple-
menting acid removal, NHERF1 enhances the local activ-
ity of the neutral phosphate transporter-2 (Npt2)
providing the essential component phosphate to the
osteoblast (Wang et al. 2013) for phosphate secretion,
mainly as ATP and ADP; calcium moves by facilitated
diffusion (Blair et al. 2011). To support bone mineraliza-
tion in the osteon, a complete, high-capacity pathway for
proton extraction from the matrix through the osteoblast
is required; NHEs neutralize large cellular acid loads, but
do not mediate H+ entry.
We studied expression of proton transporters in mes-
enchymal stem cells and in mineralizing osteoblasts by
cRNA gene screens. It is established that ClC-5 (Picollo
and Pusch 2005; Scheel et al. 2005) and ClC-3 (Guzman
et al. 2013) function as chloride–proton exchangers, and
the chloride–proton antiporter ClC-3 emerged as a key
candidate supporting H+ entry into osteoblasts, along
with large but lesser quantities of ClC-5. A role for CLCs,
including ClC-3, in acidification of epithelial cells is
established in other contexts (Claud et al. 2008). We
studied the role of these transporters in bone mineraliza-




Genome-wide expression screening was as described
(Robinson et al. 2010), using isolated RNA to make dou-
ble-stranded cDNA, from which biotin-labeled cRNA was
made and hybridized to the DNA array on glass. The
Hu145 133.2 probe set of 54,676 cDNAs, 20 replicates per
target, was used (Affymetrix, Santa Clara, CA). Presence of
transcripts and differences between treatments were deter-
mined from the signal and variation in each assay replicate,
with statistical confidence indicated.
ClC-3 knockout mice
Mice with a knockout allele replacing 13 bp of exon 6
and all of exon 7 with an insert including neomycin resis-
tance were the kind gift of Fred Lamb, Vanderbilt Univer-
sity (Dickerson et al. 2002). The animals have a mixed
129/Sv and C57B1/6J background. Knockout, wild-type,
and heterozygote littermates were used. For analysis of
bone growth in situ, animals were labeled with 25 lg/g
body weight with calcein at 4 and 1 day prior to sacrifice,
to show bone formation as fluorescent bands in frozen
sections of bone as described (Liu et al. 2012).
Human mesenchymal stem cells and
osteoblasts
Cells, pretested media, and supplements (Bullet kit) were
from Lonza (Walkersville, MD). The hMSCs used were
from a 22-year-old female; human osteoblasts were from
an 11-year-old female. All cell culture was at 37°C, in 5%
CO2 humidified air, and media were replaced each 2–
3 days unless noted. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) with 5.5 mmol/L of
glucose, L-glutamine, sodium pyruvate, 10% fetal bovine
serum, 30 lg/mL of ascorbic acid, 30 lg/mL gentamicin,
and 15 ng/mL amphotericin-B.
Mouse MSC
Mouse MSCs were isolated as described (Liu et al. 2012).
Bone marrow from 6-month-old mice was collected by
flushing femora and tibiae with RPMI 1640, 12% FBS, and
antibiotics. Disaggregated cells were filtered to remove
clumps, and plated. At 3 h, nonadherent cells were washed
off and replated. Cells then adherent on day 2 were washed
and grown in mouse MesenCult medium with serum
(StemCell Technologies, Vancouver, Canada). At 80%,
confluence cultures were trypsinized and replated at
5 9 105/cm2 and grown in DMEM with 5.5 mmol/L of
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glucose, FBS, and antibiotics. MSCs were used at passages
5–10. Osteoblast differentiation was induced by 30 lg/mL
ascorbic acid, 200 nmol/L hydrocortisone, and 10 mmol/L
glycerol-2-phosphate, with FBS reduced to 10%.
Lentivirus
A pLKO shRNA lentiviral plasmid for mouse was pur-
chased as Escherichia coli bacterial stock (ClC-N5 TRC
shRNA 69494, Sigma, Saint Louis, MO), containing the
shRNA CCGGCCTATGATGATTTCAACACAACTCGAG
TTGTGTTGAAATCATCATAGGTTTTTG, GFP, puromy-
cin, and ampicillin resistance. A colony was isolated
and grown in Luria broth with ampicillin; plasmid was iso-
lated by alkaline lysis; endotoxin was removed by nonionic
detergent phase separation (MiraCLEAN, Mirus-Bio,
Madison, WI). Vector preparation and titration were as
described (Sena-Esteves et al. 2004; Geraerts et al. 2005;
Ravi et al. 2015), and packaged using commercial envelope
and packaging plasmid preparations (Addgene, Cambridge,
MA). High-efficiency plasmid delivery was obtained using
TransIT-LT1 (Mirus-Bio, Madison, WI) in serum-free
MEM (OptiMEM, Sigma) with 3 lL of TransIT-LT1 per
lg of DNA, incubated with the plasmids for 30 min. This
mixture was incubated with packaging cells, HEK293T at
passages 2–5, in DMEM with 25 mmol/L of glucose and
antibiotics, overnight. Medium containing viral particles
was collected every 24 h and stored at 4°C, filtered through
0.45 lm cellulose and concentrated with 15 kD retention
centrifugal filters (Amicon, Millipore, Billerica, MA). Virus
titer was determined by anti-p24 ELISA (Lenti-X p24
Rapid Titer, Clontech, Mountain View, CA).
Viral transduction
Infection was as described (Wein et al. 2008). MSCs were
transduced at 60–70% confluence with lentivirus in mini-
mal medium volume 6 lg/mL of 1,5-dimethyl-1,5-dia-
zaundecamethylene polymethobromide (Polybrene,
Sigma). Calculated multiplicity of infection was 9. Cells
were placed in growth medium 24 h after the transduc-
tion. Cells were selected using 2.5 lg/mL puromycin for
7 days, beginning 48 h after transduction.
Protein extraction, western blots, and
in situ labeling
Cells (2 9 106) were lysed on ice for 5 min with RIPA buf-
fer (10 mmol/L Tris, 1 mmol/L EDTA, 0.5 mmol/L EGTA,
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
140 mmol/L NaCl at pH 8), with proteinase and phos-
phatase inhibitors. Lysates were sonicated and cleared by
centrifugation. Protein concentration was determined by
bicinchoninic acid (Thermo Fisher) binding. After heating
5 min at 95°C in sample buffer, aliquots, 40 lg or as stated,
were separated on 12% SDS-polyacrylamide gels in
Laemmli buffers. Proteins were transferred to polyviny-
lidine-derivitized nylon; unreacted groups were neutralized
in 50 mmol/L Tris, 140 mmol/L NaCl, 0.05% poly-
oxyethylene-20-sorbitan laurate (Tween 20), pH 7.4
(TBST) with 5% nonfat dry milk overnight at 4°C. Mem-
branes were rinsed with TBST and incubated with primary
antibodies: goat polyclonal anti-ClC-5 D-17, recognizing a
ClC-5-specific internal epitope (Santa Cruz, Santa Cruz,
CA), 1:150, or rabbit polyclonal anti-ClC-3 raised to amino
acids 80–125 of human ClC-3 (Bioss, Woburn, MA), 1:400,
or mouse anti-b-actin (Sigma) 1:40,000 overnight at 4°C.
Unbound antibody was washed off with TBST; secondary
antibodies were added 1:40,000 for 1 h: horseradish peroxi-
dase-conjugated (HRP) goat anti-rabbit IgG or HRP don-
key anti-goat IgG (Jackson ImmunoResearch, Westgrove,
PA), or HRP anti-mouse IgG (Sigma). The membranes
were washed with TBST and protein bands were revealed
by enhance chemoluminescence substrate (Life Technolo-
gies, Carlsbad, CA, USA). For in situ labeling of ClC-3/5,
protocols used frozen sections of mouse bone and the anti-
CLC primary antibodies as in western blots, and fluorescent
second antibodies and photographed in an inverted fluo-
rescence microscope using a 409 oil objective as described
(Palagano et al. 2015). Sections of the mouse bone were
fixed with cold acetone, decalcified with 10% sodium
citrate; in this case, anti-ClC-3 was used at 1:100 dilution
and anti-ClC-5 at 1:25. Secondary antibodies were donkey
anti-goat Cy3 and donkey anti-Rabbit Alexa 488, both at
1:500 (Jackson ImmunoResearch, West Grove, PA and
Invitrogen, Carlsbad, CA, respectively). Nuclei were stained
with Hoechst 33342 (Thermo Fisher, Pittsburgh PA).
RNA and DNA extraction and PCR
Messenger RNA was isolated by oligo (dT) affinity
(RNeasy; Qiagen, Valencia, CA). First-strand cDNA was
synthesized with Moloney murine leukemia virus reverse
transcriptase (Superscript III, Life Technologies), and ran-
dom hexamer primers, 10 mM DTT, and recombinant
RNase inhibitor (RNaseOUT, Life Technologies). Quanti-
tative RT-PCR was performed using cDNA as the template
in 25 lL reaction mixtures with premixed SYBR green,
dNTPs, buffer, Taq DNA polymerase (SYBR Green Master
Mix; Stratagene/Agilent, Santa Clara, CA) with 1 lL of first
strand cDNA and 250 nmol/L primers (Table 1). Expres-
sion relative to mouse b-actin or human glyceraldehyde-3-
phosphate dehydrogenase cDNA was calculated as
described (Robinson et al. 2009). Product sizes were veri-
fied by electrophoresis on 2% agarose. Unless noted, PCR
used 94°C denaturation for 2 min, 57°C annealing for
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30 sec, and 72°C elongation for 1 min, for 36 cycles, and
duplicate assays each run in duplicate were performed.
DNA was isolated by homogenization in denaturing buffer
and binding on silica glass columns (EZNA DNA/RNA Iso-
lation, Omega BioTek, Norcross, GA). PCRs contained
1 lL of DNA and 0.5 unit of Taq polymerase (Platinium
Taq, Invitrogen, Carlsbad, CA).
Histomorphometry, histochemistry, and
in situ labeling
Alkaline phosphatase activity was determined using
7-bromo-3-hydroxy-2-naphthoic-O-anisidide (naphthol
AS-BI phosphate) substrate, reacted with fast blue-to-
precipitate blue insoluble product, at pH 9.5 (leukocytes
alkaline phosphatase kit, Sigma). Von Kossa silver stain for
mineral used cell cultures fixed in 3.7% formaldehyde for
2 min. Mineral was stained with 2% AgNO3 under UV
light for 10 min. Animals were labeled with 25 lg/g of ani-
mal weight of calcein 4 days and 1 day prior to sacrifice.
Frozen sections of vertebrae, 4-lm thick, were obtained
using carbide blades and a tape transfer system (CryoJane;
Instrumedics, St. Louis, MO). Histomorphometric analysis
was as described (Robinson et al. 2012).
Statistics
Unless stated, the data are mean  SD. Individual compar-
isons used Student’s t-test, multiple comparisons used
analysis of variance, and P ≤ 0.05 is reported as significant.
Results
The chloride/hydrogen exchanger ClC-3 is
strongly expressed in mineralizing
osteoblasts; ClC-5 occurs at significant
levels
Previously we identified NHE1 and NHE6 as massively
expressed sodium–hydrogen exchangers in the basolateral
surface of mineralizing osteoblasts (Liu et al. 2011). These
cells form the epithelium-like boundary on the osteon
(Graphical Abstract); only this surface is exposed for
release and efflux of protons to the extracellular compart-
ment (Liu et al. 2012). The other surface of the osteo-
blasts, the apical membrane, abuts the bone matrix
compartment. We hypothesized that it must support equal
and regulated H+ influx from matrix into the osteoblast.
Using Affymetrix cRNA microarrays (Robinson et al.
2010) we compared expression for undifferentiated
human MSC and osteoblasts (Fig. 1A). There was, in the
human cells, a striking change of ClC-3 expression in
MSC, with a median signal in MSC of 29 with P value
for expression from 0.12 to 0.35, to a median signal in
mineralizing osteoblasts of 1800 with p values uniformly
<0.0002. A second CLC, ClC-5, was also increased in
mineralizing osteoblasts, but at lower levels, with convinc-
ing P values of 0.002–0.004. The same gene screens
revealed the increases in NHE1 and NHE6 to about 1000
with P values of <0.0002 in osteoblasts, as reported (Liu
et al. 2011, 2012). Other CLCs and other potential regu-
lated inward proton transporters were not strongly
expressed in human osteoblasts (not illustrated). We con-
cluded that expression of ClC-3 and ClC-5, together with
NHE1 and NHE6 at the basolateral membrane, might
form the basis of a coordinated transcellular system to
move H+ produced by precipitation of hydroxyapatite in
the matrix. This approach assumes that the major mecha-
nisms have a strong overlap in humans and mice used in
subsequent work; this assumption was validated by PCR
assays comparing the species (Fig. 1B–C). In both human
and murine osteoblasts, both ClC-3 and ClC-5 mRNAs,
were increased in mineralizing cells, and subsequently
were studied in murine MSCs and osteoblasts.
We followed this with in situ antibody labeling of ClC-
3 in bone from Clcn3+/+ and Clcn3/ mice (Fig. 1D).
The ClC-3 labeling was consistent with osteoblast mem-
brane expression of ClC-3 in surface osteoblasts and in
the membranes of the canalicular system. Osteocytes bur-
ied in mineral, from earlier layers of bone formation,
maintain processes in these canaliculi, connecting to the
surface layer of osteoblasts synthesizing new matrix. In
Table 1. Primer sequences and predicted PCR products
Gene GenBank Forward Reverse bp
Actin NM_007393 50GATATCGCTGCGCTGGTCGTC 50ACGCAGCTCATTGTAGAAGGTGTG 275
Alp NM_007431 50ATCGGAACAACCTGACTGACCCTT 50ACCCTCATGATGTCCGTGGTCAAT 131
Clcn3 AF029347 50CCAAGACCCCGCTTCAATAA 50CGAGTCCCGCAGATTAAAGA 122
Clcn5 NM_016691 50GAGGAGCCAATCCCTGGTGTA 50TTGGTAATCTCTCGGTGCCTA 101
Col1 NM_007742 50TTCTCCTGGCAAAGACGGACTCAA 50AGGAAGCTGAAGTCATAACCGCCA 159
Ocn NM_007541 50ACCATCTTTCTGCTCACTCTGCTG 50TATTGCCCTCCTGCTTGGACATGA 117
Runx2 NM_001145920 50-ATGATGACACTGCCACCTCTGAC 50ACTGCCTGGGGTCTGAAAAAGG 105
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bone from Clcn3/ animals labeling was absent (Fig. 1D,
right), demonstrating that the strong ClC-3 labeling in
the wild-type animal bone is not an artifact.
Surprisingly, the bone phenotype of Clcn3/ animals,
at least at the 3-month’s age studied, was very mild. By
visual inspection the bones of each animal appeared unre-
markable and very similar; microcomputed tomography
showed differences in the order of 5%, with a trend to
lower bone volume, trabecular thickness, and increased
trabecular spacing in the Clcn3/ relative to wild-type
animals, but none of these reached significance (n = 8,
not illustrated). These results were puzzling, since if ClC-
3 is essential to acid transport an impressive phenotype
would be expected. Bone formation in Clcn3+/+ and Clc-
n3/ animals was compared directly using calcein label-
ing of mineral deposition in vivo (Fig. 1E–F). Blinded
measurement of calcein double labels, done 5 and 1 days
before sacrifice, showed that the Clcn3/ mice have
anomalous bone mineral deposition, limited to blurring
of mineral deposition. Note that broadened calcein lines
reflect delayed mineralization rather than increased min-
eralization; nonmineralized matrix accumulates in bone
mineralization defects including vitamin D deficiency. We
hypothesized that the mild phenotype reflects that ClC-5
might compensate for ClC-3 loss.
ClC-3 knockout osteoblasts have greatly
increased ClC-5 expression
Not having access to ClC-5 animals, we undertook study
of bone formation by MSCs in culture. The MSCs from
ClC-3 animals could then be treated with lentivirus
Figure 1. Expression of ClC-3 and ClC-5 in mineralizing osteoblasts, and the mild bone phenotype of the ClC-3 knockout mouse.
(A) Microarray gene screens of mineralizing osteoblasts showed strong expression of ClC-3 and ClC-5, greatly increased over expression in
precursor MSC. The black line labeled background is the median fluorescent signal of nonexpressed genes. This is extremely strong expression
for this class of genes in many folds that of cells using ClC-3 in acid vesicles within the cells. Quantitative PCR confirmed amplification of ClC-3
and ClC-5 in mineralizing human osteoblasts relative to growing cells (B); ClC-3 and ClC-5 mRNAs increased with differentiation. ClC-3 and
ClC-5 in murine MSC and osteoblasts (C) showed the same pattern of expression; in this case differences for ClC-5 did not reach significance
(P = 0.09). In all cases the pattern of CLC expression confirmed gene screening (A). Larger changes in ClC-5 expression occurred in replicates
and in Clcn3/ osteoblasts (see Fig. 2F). (D) Fluorescent ClC-3 antibody labeling of mouse bone from wild-type and ClC-3 knockout animals.
Each field is 350 lm across, and shows a section of cortical bone. In the wild type (left) there is strong labeling in the surface layer of
osteoblasts at the apical surface (arrows); labeling carries down into the canalicular system connecting the osteocytes and osteoblasts
(arrowheads). That the unusual cell membrane pattern is actually ClC-3, and not artifact, shown by comparison with the ClC-3 knockout bone
(right). The weak red at the bone periphery is an artifact due to the edge of the dense matrix. (E) Characterization of bone formation in the
ClC-3 knockout mouse, in 3-month-old animals labeled with calcein 5 and 1 days before sacrifice, showed only minor effects, including slight
broadening of the calcein labels. (F) Blinded measurements of interlabel distance showed a small, but significant, increase in the ClC-3
knockout animals. N = 20, mean  SEM.
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shRNA to reduce ClC-5, to determine the effect of low
expression of both CLCs on mineral deposition in cul-
ture. This might be necessary in any case, since if the
function of CLCs is essential, the bone defect of ClC-3
and ClC-5 absence might be lethal. To confirm the geno-
type of MSCs from ClC-3 mice, the KO and wild-type
(WT) alleles of ClC-3 were identified by PCR with geno-
mic DNA using primers showing that the targeted region
in exons 6–7 was absent in cell cultured from the knock-
out mice (Fig. 2A), with targeting insert neomycin resis-
tance shown as a positive control. Western blotting
revealed low levels of ClC-3 protein in Clcn3/ mouse
(not shown); defective protein is present, but nonfunc-
tional (Dickerson et al. 2002). We purchased a plasmid
with shRNA targeting ClC-5, containing a green fluores-
cent protein insert, puromycin and ampicillin resistance,
and packaged it in lentiviral particles. Lentiviral infection
was monitored by GFP fluorescence (Fig. 2B). After initial
infection, 25% of cells had GFP; after puromycin selection
and 2 weeks in culture, all cells were GFP positive
(Fig. 2B, lower panel). In wild-type MSCs, ClC-5 was pre-
sent at low levels (Fig. 2C, left). However, in osteoblasts
from Clcn3/ animals, ClC-5 protein was greatly
increased by an unknown mechanism (Fig. 2C, middle).
After infection with the viral vector ClC-5 protein expres-
sion was suppressed by shRNA. This was not complete,
but to levels similar to ClC-5 in wild-type cells (Fig. 2C,
right). These results were consistent with quantitative
PCR in osteoblasts cultured for 1 week in osteoblast dif-
ferentiation medium (Fig. 2D). Wild-type controls
infected with scrambled shRNA showed no difference rel-
ative to the uninfected wild type (not illustrated). That
ClC-5 mRNA and protein is greatly amplified in Clcn3/
animals, which have a near normal bone phenotype
(Fig. 1E–F) suggested that ClC-5 might functionally com-
pensate for ClC-3 loss. If this hypothesis is correct, ClC-5
and ClC-3 should occur in similar distribution in osteo-
blasts and osteocytes. This was the case, with antibody
labeling of ClC-3 and ClC-5 in bone of normal animals
having and overlapping distribution (Fig. 2E). Thus, in
the osteon, the two channels are codistributed and might
compensate each other to a significant extent. Additional
studies of ClC-5 mRNA in wild-type and Clcn3/ cells,
in growth medium and in differentiation medium, with
and without lentiviral ClC-5 shRNA confirmed greatly
increased ClC-5 in Clcn3/ cells, and that the shRNA
reduced ClC-5 by about 80% in either cell type (Fig. 2F).
C57 black mouse cells and wild-type Clcn3+/+ cells,
mainly 129/Sv, showed the same pattern of ClC-3 and
ClC-5 expression, with or without lentiviral ClC-5 knock-
down, indicating that there is probably not a strong
strain-specific effect on CLC expression in mice (not
shown). The reason for the residual ClC-5 is uncertain,
but likely is due to insufficient hsRNA to suppress the
very strong ClC-5 expression. We next studied bone for-
mation in Clcn3/ cells with and without ClC-5 hsRNA
relative to bone formation in wild-type cells.
Effect of eliminating ClC-3 and suppressing
ClC-5 on bone formation in vitro
To understand the importance of increased ClC-5 expres-
sion in MSC cultured from ClC-3 mice we applied
shRNA via lentivirus infection to reduce ClC-5 expression
in bone-forming cultures from Clcn3/ mice, and char-
acterized the resulting bone differentiation. The pretested
shRNA-GFP-puromycin resistance construct was designed
to target mouse ClC-5, and showed specific protein sup-
pression during differentiation in our mouse osteoblast
cultures (Fig. 2F). Retention of 10–20% of the very high
ClC-5 expression reflects a common effect with highly
expressed genes, where a large amount of mRNA produc-
tion and processing overwhelms the dicer system’s ability
to degrade shRNA complexes, just as occurs in over-
whelming viral infections. Notwithstanding that ClC-5
suppression was imperfect, the method made cells with
suppressed ClC-5 similar to levels in wild-type cells,
which we hypothesized would significantly affect bone
differentiation in ClC-3 negative, ClC-5 knockdown cells
on osteoblast differentiation. Analysis of bone-related
mRNAs showed that expression is, as expected, increased
by differentiation in osteoblast-promoting medium. Bone
protein and promoter expression was highest in wild-type
cells (Fig. 3A–F). For the bone transcription factor
osterix, expression was invariant with ClC-3/5 status; the
transcription factor RunX2 was highest in wild-type cells.
Alkaline phosphatase, osteoprotegerin, and bone sialopro-
tein were significantly increased over growing cells in
wild-type and ClC-3/5 modified cells, but were mostly
highest in the wild type. This may reflect in part different
time courses of production in the different cell types:
alkaline phosphatase, a durable ectoenzyme had strong
and uniform activity at 2 weeks (Fig. 3G) in wild-type
and CLC-modified cells. Type I collagen was highly
expressed including in all of the cell types; in any osteo-
blast culture a minority of cells are active in bone forma-
tion; relatively highly expressed proteins are less specific
markers for that reason.
In contrast, by undertaking careful analysis of mineral-
ization in culture, we uncovered a remarkable aspect of
mineralization in Clcn3/ cells, possibly due to the
increased ClC-5 expression in these cells (Fig. 2). Specifi-
cally, mineral production was widespread and occurred in
a distinct, fine trabecular pattern with sharp boundaries
(Fig. 3H, bottom middle panel). In spite of many
attempts to formulate trabecular bone bioreactors,
2015 | Vol. 3 | Iss. 11 | e12607
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mineralization always has been in patchy, round, or
spherical nodules and bone produced is not ideally suited
for implantation. The highly branching trabeculae were a
characteristic of the cells from ClC-3 mice and might
indicate a practical method of creating trabecular bone
in vitro (see Discussion); it occurred uniformly in ClC-3
cells from separate MSC isolations and in over a dozen
separate tissue culture differentiation assays. In bone
differentiation in vitro, formation of solid bone tissue
has been inconsistent, unreliable (Jakob et al. 2012), and
Figure 2. Preparation of ClC-3 and ClC-3/5 null mesenchymal stem cells. (A) PCR to probes in exons 6–7 showing complete removal in MSC
from ClC-3 knockout animals. The neomycin control verifies presence of the insert (see text). (B) Green fluorescent protein to document
lentiviral infection of MSC with plasmid carrying both GFP and ClC-5 shRNA. Initial infection was ~25% efficient; puromycin selection increased
the proportion of knockdown cells to quantitative (lower panel). However, shRNA degradation of target was ~80% efficient, see PCR data
following. (C) Western blot of ClC-5 wild-type and Clcn3/ MSC, with and without lentiviral knockdown of ClC-5, in osteoblast differentiation
medium 2 weeks. The increase in ClC-5 in the ClC-3 null cells is not an artifact, see PCR assays following. With lentiviral shRNA, ClC-5 protein
declined 80–90% relative to matched cultures without shRNA, to levels similar to wild-type ClC-5 expression (left). One of two western blots
with similar results is shown. (D) Effect of ClC-3 KO on ClC-3 and ClC-5 mRNA expression. For ClC-3, primers for exons 1–2 detect a region
unaffected by the knockout (in which a portion of exon 6 and exon 7 are deleted); this shows the amount of nonfunctional ClC-3 mRNA,
which is not changed significantly in the knockout. The probe for ClC-5 amplifies a portion of exon 7; note the increase in ClC-3 knockout
cells. The primers are listed in Table 1. Mean  range, n = 2 is shown, in one of two experiments with similar results. (E) Antibodies
demonstrate that ClC-3 and ClC-5 occur in wild-type murine bone in essentially the same distribution, in the canalicular system, and at the
basolateral surface of the osteoblasts. High power fields, 400 microns across. Distribution of ClC-3 is shown in green, ClC-5 in red, and the
two merged are shown at the top. (F) Effect of lentiviral shRNA on ClC-5 in wild-type littermate and ClC-5 knockout MSC, in growth medium
(left of each group) and after 1 week in differentiation medium. Differences relative to the growth medium controls, P < 0.05, *, of P < 0.01.
One of two experiments is shown, each with n = 2.
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typically unimpressive even when best results are shown.
Importantly, in keeping with the hypothesis that Cl/H
exchange supports mineral deposition, mineral was uni-
formly absent in matched 2 week cultures of Clcn3/
cells with ClC-5 shRNA.
Properties of bone matrix in CLC defective
cells at high resolution
Because of the remarkable trabecular nature of mineral-
ization by the ClC-3 cultured MSCs we examined these
cultures at high-magnification and quantified alkaline
phosphatase activity and mineral density. In all cell types,
alkaline phosphatase occurred in fine linear patterns con-
sistent with cell surface-associated activity (Fig. 4A), in
keeping with its cell surface expression as established in
other contexts (Magnusson et al. 1999). In the Clcn3/
cells dense alkaline phosphatase activity occurred adjacent
the trabecular bone, in keeping with its distribution at
the bone-attached osteoblast surface in vivo (Fig. 4A,
middle, arrows). Quantitative alkaline phosphatase activ-
ity showed minor increases in activity in the cells with
modified CLCs, but no difference between Clcn3/ and
Clcn3/, ClC-5 shRNA (Fig. 4B).
Silver stain for bone mineral was strongly positive in
wild-type and ClC-3 cells. At high power, gaps in the
mineral were observed consistent with bodies of cells
becoming osteocytes that are incorporated in the mineral-
ized matrix (Fig. 4C, left and middle panels). In Clcn3/
, ClC-5 shRNA cells, no significant mineral as deposited.
There were minor amounts of linear labeling at high
power, in the morphology associated with the cell surface.
We conclude that this most likely reflects that, in the
presence of the glycerol-2-phosphate substrate at high
concentration (10 mmol/L), some calcium–phosphate
precipitate occurs outside of cellular mineral transport,
similar to calcification of hypertrophic cartilage. Overall
mineral deposition in wild-type and Clcn3/ cells was
essentially the same at 2 weeks, notwithstanding the pro-
found difference in the pattern of mineralized matrix.
The Clcn3/, ClC-5 shRNA cells made no significant
mineral. Following the mineralization in Clcn3/ cells
for an additional week extended the mineral deposition
to a sheet-like morphology with windows (Fig. 4E), and
it was clear that the fine patterning boundaries for bone
formation were defined before mineralization was com-
plete (arrows, Fig. 4E).
Discussion
A keyword search for idiopathic osteoporosis in the data-
base Medline returns 800 reports that include a smatter-
ing of incomplete tubular acidosis and calcium wasting
hypotheses, but in most cases have no rationale for the
finding of osteoporosis. There is a clear problem with
osteoporosis not fitting known categories of matrix
defects. This likely reflects the existence of many mineral
transport defects that, if not lethal, have mild or moder-
ate phenotypes. Since humans are long-lived, defects
accumulate with time to produce skeletal fragility, and
cases may have multifactorial causes.
In an attempt to “close the loop” regarding one major
incomplete system, acid elimination to drive mineraliza-
tion to completion (Blair et al. 2011), we produced con-
clusive data that without ClC-3 and ClC-5, osteoblasts
cannot mineralize in vitro. It is likely that for further
in vivo studies, cell-specific knockouts may be required;
mutations of Clcn5 cause Dent’s disease (Silva et al. 2003)
and constitutive Clcn3/Clcn5 double knockout animals
might be lethal if the expected severe skeletal mineraliza-
tion defect occurs.
Precedents in bone include that ClC-7 mediates
exchange of extracellular H+ for Cl and is required for
normal osteoclast function (Kornak et al. 2001; Sobacchi
et al. 2013). In addition, in a singular study (Wang et al.
2010), CLCs 3, 4, and 5 were hypothesized to drive osteo-
blast differentiation. Each CLC, when overexpressed in
MC3T3-E1 osteoblast-like cells, localized to peripheral
membranes and was associated with increased mineral-
ization, in the mineralization pattern seen in normal
Figure 3. Effect of ClC-3 absence, and of ClC-5 knockdown in Clcn3/ cells, on bone matrix production and mineralization.
(A–F) Quantitative PCR for major osteoblast proteins in growing wild-type cells and in wild-type, Clcn3/ cells, and Clcn3/ cells with lentiviral
ClC-5 shRNA, at 2 weeks in osteoblast differentiation medium. (A) Osterix. (B) Alkaline phosphatase. (C) Col-Ia1 . (D) Runx2. (E)
Osteoprotegerin. (F) Bone sialoprotein. The proteins are expressed less in growing cells, and highest in wild type. In some, but not all, cases,
expression is reduced in the knockout/knockdown cells, but remains higher than in the growing cells. (G–H) Alkaline phosphatase and mineral
production in cell cultures. Round fields are whole wells of six-well plates; micrographs are 1.6 mm across. (G) Alkaline phosphatase activity
was similar in wild-type cells or Clcn3/ cells with and without ClC-5 shRNA. Alkaline phosphatase distribution was more uniform in
Clcn3/  ClC-5 knockdown cells. The lower panels are low power micrographs in cultures 14 days in osteoblast differentiation medium. (H)
In whole cultures, mineral appeared nodular in the control, was more uniformly distributed in Clcn3/, cells, and was absent in the Clcn3/
cells with ClC-5 shRNA at 14 days in osteoblast differentiation medium. Low-power micrographs showed that the Clcn3/ cells had a
remarkable trabecular pattern (see Fig. 4). This pattern of bone differentiation was remarkably consistent in different isolates of Clcn3/ cells,
in two MSC isolates and in several replicates of each isolate.
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wild-type cells. Furthermore, the same group recently
showed that overexpressing ClC-3 in MC3T3-E1 rendered
cells susceptible to mechanical force-induced upregulation
of bone markers (Wang et al. 2015). Given the expression
of ClC-3 in canaliculi of bone (Fig. 1), and the nature of
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the role of ClC-3 in mediating formation of trabecular
structures in differentiating bone (Figs. 3, 4).
Much further work is required fully to characterize out-
ward proton transport with bone mineral formation. The
H+ gradient during mineral transport is minor, but
“uphill”; bone matrix is maintained at about pH 7.6–7.8
(Blair et al. 2011). The extracellular chloride concentra-
tion is unknown, and precipitation of mineral may leave a
hypotonic solution, requiring aquaporins or another water
transport mechanism. Furthermore, a cation is required to
drive Cl/H+ exchange, since it is electrogenic. Potassium
conductance is the likely candidate; a specific channel is
not known, and there are many candidates. Potassium
transport to drive H/Cl exchange, which is hypothetical,
and some elements of osteoblast transport that are estab-
lished, including the NHERF-1 regulatory protein, are
omitted from the graphical abstract to make the main
point clear. Additionally, chloride balance of the osteo-
blasts would be jeopardized by massive Cl/H exchange; a
compensatory mechanism must exist, possibly a KCl sym-
port. Proton balance is not a problem; transit of acid from
the osteoblast is the function of NHE Na/H exchangers at
the basolateral membranes of osteoblasts (Liu et al.,
2011), as diagramed in the Graphical Abstract. Querying
human mineralizing osteoblast cRNA screens showed high
expression of both aquaporin and KCl symport transcripts
(not illustrated); these will require specific study to vali-
date the hypothesis that they fulfill support roles during
bone synthesis in the isolated extracellular matrix com-
partment. There are many other specializations of osteo-
blasts, including high levels of expression of glutathione
peroxidases and superoxide dismutases, which may be
required to counteract free radical production during syn-
thesis of bone matrix (not shown).
We began these studies in the belief that understanding
the transport and regulatory mechanisms that support
physiologic bone formation in the osteon will fundamen-
tally change the prospect for patients who are categorized
as having idiopathic osteoporosis. However, in the course
of these studies we made an additional important obser-
vation: Osteoblasts, under conditions where the major Cl/
H antiporter is knocked out and ClC-5 expression
increased to compensate, make remarkably uniform tra-
becular bone in vitro (Fig. 4C and E). A generation of
attempts to make bone with suitable characteristics for
surgical implants has fallen short. Despite numerous types
of bioreactors containing many different types of support-
ing matrix or scaffold and mesenchymal stem cells,
getting the artificial tissue to form meaningful three-
dimensional bone has been a major challenge (Jakob et al.
2012). Problems include difficulties in MSC expansion
and decoupling of cell growth and bone matrix forma-
tion. A cell line that produces trabecular bone reliably
might greatly reduce the second problem, increasing effi-
ciency and reducing dependency on scaffolds. Note, how-
ever, that Clcn3/ cells do not produce increased matrix
relative to wild type, at least at the times studied. The dif-
ference is that bone production is widespread in a sheet
of tissue with gaps, similar to trabecular bone in the
spine. We do not yet have pathway data for why the
major difference in trabecular pattern occurs. That, trans-
lating the result to human cells, and expansion of the cul-
tures, remains to be done.
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Figure 4. Characteristics of alkaline phosphatase and mineral deposition at high power in wild type, Clcn3/, and Clcn3/ with ClC-5 shRNA
cells. All data for cultures are at 2 weeks in bone differentiation medium, except part G. (A) Alkaline phosphatase. Strong alkaline phosphatase
activity occurs in fine linear areas consistent with cell surface and cell process-associated activity in wild-type (left), Clcn3/ (middle), and
Clcn3/ and ClC-5 shRNA cells (right). In Clcn3/ cells there is dense alkaline phosphatase adjacent to much of the trabecular bone
(refractile, unstained) (arrows, center panel). Fields are 250 lm across. (B) Quantitative alkaline phosphatase activity at 3 weeks by densitometry
of four replicates, similar to Figure 3G–H upper panels. There was no difference between ClC-3 negative and ClC-3 negative ClC-5 shRNA
cells. (C) Silver stain for bone mineral. In wild-type and in Clcn3/ cells, lacunae indicate that cells incorporated in the matrix. In the Clcn3/
and ClC-5 shRNA cells, no significant mineral occurs, although minor amounts of linear labeling are seen in the pattern similar to strong cell
surface-associated alkaline phosphatase activity (A, right panel, arrows), suggesting nonspecific phosphate precipitation at sites of very high
alkaline phosphatase (see text). Fields are 250 lm across. (D) Densitometry for mineral, quantified as dark matter in transmitted light, in four
replicates of the three cell types at 2 weeks in differentiation medium. There was no difference in overall absorbance in wild-type and Clcn3/
cells, despite the remarkable difference in matrix pattern. The Clcn3/ and ClC-5 shRNA cells made no meaningful mineral. (E) A cell culture
of Clcn3/ cells as in (D) middle, but maintained in osteogenic medium for an additional week. The mineral area has expanded and now
appears in sheet-like form with windows in irregular distribution. In this large area, it is clearly seen that some of the pattern is laid out but not
fully mineralized. Magnification is the same as (D), with an expanded field, 750 lm across.
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